Citations

Clear

13603 citation(s) found for "_, _".

Prevalence, aetiology, and outcomes of native pulmonary regurgitation in the general adult population
Naser, Jwan A. , Ibrahim, Hossam, Andi, Kartik, Scott, Christopher G. , Pellikka, Patricia A. , Kennedy, Austin M , Connolly, Heidi M. , Nkomo, Vuyisile T. , Warnes, Carole A. , Jain, C. Charles , Egbe, Alexander C. , Andi, Kartik , Jain, Charles C, Borlaug, Barry A , Nkomo, Vuyisile T , Scott, Christopher , Pellikka, Patricia A , Enriquez-Sarano, Maurice , Kennedy, Austin M , Naser, Jwan A , Enriquez‐Sarano, Maurice , Pislaru, Sorin V. , Borlaug, Barry A.

Mayo Clinic

European Heart Journal - Cardiovascular Imaging | January 10, 2025 | Volume: 26 | Issue: 4 | Pages: 695-702

10.1093/ehjci/jeaf011 | PMID 39792481 Get It

Abstract Aims Pulmonary regurgitation (PR) after reparative intervention for congenital heart disease has been studied extensively. However, the burden, distribution of causes, and outcome of PR in adults is unknown. The study aimed to evaluate the prevalence, types, and outcomes of moderate/severe PR in adults in the community setting. Methods and results A total of 398 adult residents of Olmsted County who had clinically indicated echocardiography 2004–2023 at Mayo Clinic, Rochester, and had moderate or severe PR were identified retrospectively. The median age was 77 years, 48% were females, and 61 (51%) had severe PR. The age- and sex-adjusted US prevalence was 0.11% (vs. 0.67% for ≥moderate tricuspid regurgitation). Moderate/severe PR was due to pulmonary hypertension in 77%, congenital/iatrogenic in 11%, primary pulmonary valve disease in 2% (88% due to carcinoid), and idiopathic isolated in 10%. In contrast, severe PR was due to congenital/iatrogenic disease in 52%, pulmonary hypertension in 39%, primary PR in 5%, and isolated idiopathic in 3%. The all-cause mortality rate per 100 person-year was 73 in primary (mostly carcinoid) PR, 16 in pulmonary hypertension–related PR (not different vs. propensity-matched patients without PR), and 6 in isolated idiopathic PR (not different vs. matched patients without PR). Conclusion Moderate or severe PR had a lower prevalence vs. TR. The most frequent cause was pulmonary hypertension for ≥moderate PR and congenital/iatrogenic for severe PR. Mortality in patients with acquired ≥moderate PR appeared to be related to the underlying cause, with no excess mortality compared with matched patients without PR. Whether specifically severe PR confers excess mortality requires future investigation.
Preclinical and Toxicology Assessment of ISFP10, an Inhibitor of Fungal Phosphoglucomutase (PGM)
Pellegrino, Madeline R., Bindzus, Marc, Ayyalasomayajula, Savita, Yi, Eunhee S. , Kottom, Theodore J. , Ayyalasomayajula, Savita, Limper, Andrew H.

Mayo Clinic

No container title available | January 10, 2025 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.1101/2025.01.07.631740 | PMID 39829820 Get It

ABSTRACT Background and Objective Previously, the novel small molecule ISFP10 has been shown to inhibit fungal phosphoglucomutase (PGM) activity in Aspergillus fumigatus and Pneumocystis spp. With 50-fold selectivity over the human PGM molecule due to the presence of a unique yet conserved cysteine residue present in a number pathogenic fungal PGMs, use of this compound may provide a novel broad-spectrum approach to treating fungal infections. Accordingly, we sought to determine the tolerability in test animals receiving this compound, as well as the potential antifungal activity of ISFP10 on cultures of the common fungal pathogens Candida albicans and Candida glabrata . Methods C57BL6 mice received once daily intraperitoneal (IP) injections of 100 mL of vehicle control (DMSO) or ISFP10 at a concentration of 10 mg/kg. Body weights were recorded daily for 7 days of treatment. On the final day, mice were weighed and euthanized. Postmortem blood collection was conducted via cardiac puncture and distributed to EDTA and lithium heparin tubes for complete blood count (CBC) and comprehensive blood chemistry panels, respectively. Liver, kidney, and lung tissue were also harvested and placed in 10% formalin for H&E staining and blinded histopathologic scoring. Lung samples were further analyzed for proinflammatory cytokines using enzyme-linked immunosorbent assays (ELISA) and quantitative PCR (qPCR). Furthermore, ISPF10 was tested for antifungal activity via 8-hour growth curve analysis in a concentration-dependent fashion against Candida albicans and Candida glabrata . Results There was no significant difference in the daily or final body weights of the mice receiving 10 mg/kg of ISFP10 compared to those of the vehicle control group. Extracellular matrix (ECM) transcripts for IL-6 and TNFα were statistically similar via qPCR. ELISA results of proinflammatory cytokines for IL-6 was not significant whereas TNFα levels in lung tissue from the ISFP10 treatment group were significantly reduced, indicating a potential anti-inflammatory effect of ISFP10 at this dosage. Overall, blood chemistry and CBC analysis revealed no overall significant differences between the two groups, except for increased neutrophil counts and decreased potassium levels in samples collected from ISFP10 treated animals compared to the vehicle control group. These laboratory abnormalities were not of clinical significance to the test animals. Blinded histopathological examination revealed no abnormalities or evidence of critical organ toxicity from all groups. Inhibition of C. albicans and C. glabrata culture growth by ISFP10 was concentration-dependent in YPD liquid media containing the ISFP10 compared to vehicle control. Conclusions Our preliminary testing of ISFP10 revealed no inherent safety or toxicology concerns within the observed parameters. These data further support significant culture suppressive activity against C. albicans and C. glabrata . Taken together, these observations of ISFP10 further indicate that targeting PGM might be a novel and viable therapeutic strategy for serious fungal infections. Key points An inhibitor specific to fungal PGM enzymes, termed ISFP10, was generally well tolerated when administered via intraperitoneal (IP) injection in mice. ISFP10 displays antifungal activity in a concentration-dependent manner against C. albicans and C. glabrata .
A Qualitative Assessment of Barriers, Facilitators, and Outcomes in a Simulation-Based Collaborative Quality Improvement Program
Alletag, Michelle, Kant, Shruti, Ittersum, Wendy L. Van, Walls, Theresa A. , Montgomery, Erin , Mannenbach, Mark S., Auerbach, Marc , Auerbach, Marc A, Anderson, Hannah L. Kakara

Mayo Clinic

Pediatric Emergency Care | January 9, 2025 | Volume: 41 | Issue: 4 | Pages: 273-280

10.1097/pec.0000000000003321 | PMID 39787042 Get It

Objectives: ImPACTS (Improving Acute Care Through Simulation) is a collaborative simulation-based program partnering pediatric specialty centers (“hubs”) with general emergency departments (GEDs) to improve pediatric acute care. Objective measurements of ImPACTS, such as evaluating Pediatric Readiness Score (PRS) and simulation-based outcome improvements, have been reported previously. Barriers to and facilitators of program involvement and the downstream effects of the program have not been previously described. This study explores these aspects and key drivers for successful collaboration. Methods: The authors performed open coding of semistructured interviews of hub team members and pediatric emergency care coordinators (PECCs) from community GED “spokes.” We then identified and explored themes within the categories of barriers to, facilitators of, and barrier mitigation strategies for successful partnerships from the perspectives of both groups. Results: Analysis generated 4 dominant themes: buy-in, communication, personnel, and logistics. Engagement, institutional support, and buy-in of site leaders and individual participants were crucial to successful implementation, without which the programs were not completed or never started. Hubs benefited from project involvement via increased local engagement in pediatric readiness, organizational support, and further buy-in from institutional leadership, allowing for the future continuation of ImPACTS and similar programs. Benefits experienced by GEDs impacted education, pediatric readiness, and clinical and financial partnerships across institutions. Additionally, spoke interviewees cited downstream effects of participation, including increased collaboration and improved relationships with hub sites as being the most impactful. Conclusion: Understanding the key drivers of all collaborators is instrumental in successfully implementing large-scale educational and quality initiatives like the ImPACTS program.
Infections, autoimmunity and immunodeficiencies are the leading etiologies of non-cystic fibrosis bronchiectasis in adults from the southwest of Colombia.
Zea-Vera, Andrés Felipe , Rodríguez, Carmen , Giraldo, Sebastián, Chacón, Mario Alejandro , Guerrero, Lázaro Gregorio Guerrero , Mosquera, Ricardo , Serna, Raúl Andrés Vallejo , Vargas-Cely, Fabio Samir , Rengifo, María A., Bonelo, Anilza , Parra, Maximiliano , Zea-Vera, Andrés F , Rodríguez, Carlos Andrés , Guerrero, Luis Fernando , Vallejo, Raúl Andrés , Vargas-Cely, Fabio Samir , Parra, Maximiliano , Giraldo, Sebastián, García, María Andrea, Rengifo, María Alejandra

Mayo Clinic

Biomédica | January 9, 2025 | Volume: 44 | Issue: Sp. 2 | Pages: 80-93

10.7705/biomedica.7500 | PMID 39836848 Get It

Introduction. Non-cystic fibrosis bronchiectasis is a complex medical condition with multiple etiologies, characterized by chronic productive cough and radiologic evidence of airway lumen dilation and wall thickening. Associated exacerbations and declining lung function contribute to increasing disability and mortality. There are no data about the prevalence of non-cystic fibrosis bronchiectasis etiologies in the Colombian population.Objective. To investigate non-cystic fibrosis bronchiectasis etiology and clinical characteristics in adults evaluated in the southwest of Colombia.Materials and methods. We conducted a cross-sectional, non-interventional study. Subjects diagnosed with non-cystic fibrosis bronchiectasis were referred to by theirhealthcare providers and then enrolled between October 2018 and April 2021. Medical records and radiological studies were evaluated. Participants underwent laboratory tests, including complete blood count, serum immunoglobulin levels, and, in some cases, additional tests.Results. We included 161 subjects. The average age was 50 years old, and 59% were females. Bronchiectasis etiology was identified in 84.6% of the cases. Postinfectious(34.6%) and immune disorders (25.3%), represented by autoimmunity (13.6%) and immunodeficiency (11.7%), were the leading causes. Gender differences were noted in autoimmune (females: 18.8% versus males: 6.1%, p = 0.021) and immunodeficiency-related bronchiectasis (males: 21.2% versus females 5.2%, p = 0.002). Immunodeficiencies-associated bronchiectases were more frequent in subjects under 50 years of age, while chronic obstructive pulmonary disease-associated bronchiectases were common in subjects over 50 years of age.Discussion. The etiologies of non-cystic fibrosis bronchiectasis in Colombia are diverse, exhibiting notable differences from other global regions. Serum immunoglobulin levels and clinical immunologist consultation should be prioritized in diagnosing patients with unclear bronchiectasis etiology, particularly those with recurrent sinopulmonary infections.
Reliability of the remote digital self‐administered Stricker Learning Span, Symbols Test and Mayo Test DRIVE Screening Battery Composite
Hughes, Morgan A, Frank, Ryan D. , Fan, Winnie Z. , Christianson, Teresa J., Stricker, John L. , Fields, Julie A. , Aduen, Paula, Lucas, John A. , Graff‐Radford, Jonathan, Petersen, Ronald C. , Hughes, Morgan A, Kremers, Walter K. , Boots, Elizabeth A. , Machulda, Mary M. , Hassenstab, Jason , Graff‐Radford, Jonathan , Vemuri, Prashanthi , Jack, Clifford R. , Knopman, David S. , Stricker, Nikki H.

Mayo Clinic

Alzheimer's & Dementia | January 9, 2025 | Volume: 20 | Issue: S8 | Pages: No page available

10.1002/alz.095558 Get It

AbstractBackgroundMayo Test DRIVE (MTD): Test Development through Rapid Iteration, Validation and Expansion, is a web‐based multi‐device (smartphone, tablet, personal computer) platform optimized for remote self‐administered cognitive assessment that includes a computer‐adaptive word list memory test (Stricker Learning Span; SLS), a measure of processing speed/executive functioning (Symbols Test) and a score combining both the memory and processing speed/executive functioning measures (MTD Composite). We aimed to determine the reliability of MTD measures across follow‐up sessions.MethodIndividuals participating in this ancillary study who completed at least two and up to four complete MTD sessions were included, resulting in 1,293 participants (mean age = 70.6, SD = 11.6; mean education = 15.6, SD = 2.3; 48.6% male; 96.9% White; 99.1% non‐Hispanic; 97.1% cognitively unimpaired) from parent studies (see Table 1). MTD raw scores were winsorized at 1% and 99% to minimize the impact of outliers. Test‐retest reliability was assessed using single‐rating, absolute‐agreement, and two‐way mixed ICCs and results are described using descriptives from Koo et al. (2016). ICCs for in‐person‐administered traditional neuropsychological measures are also reported alongside MTD for a subset of participants newly enrolled into the MCSA (to ensure participants were test naïve to both MTD and in‐person tests).ResultReliability was good for the MTD Composite raw [total ICC = 0.78; see Table 2 for session‐to‐session ICCs and 95% CIs], and moderate‐to‐good for the primary outcome variables for each subtest [total ICC = 0.74 for both SLS and Symbols]. Weighting by accuracy negatively impacted reliability of Symbols and the Composite; without this weighting, MTD Composite and Symbols variables showed higher reliability (MTD Composite z total ICC = 0.80; Symbols response time total ICC = 0.84; see Table 2). Alternative methods of defining response time on Symbols showed nearly identical reliability values. SLS sum of trials (primary variable) had subtly higher reliability than separate measures of learning (1‐5 correct, max span) or delay. Reliability of remote MTD and in‐person‐administered measures and select comparisons are provided in Table 3.ConclusionMTD showed moderate to good reliability, similar to in‐person‐administered traditional neuropsychological tests. Future work will examine the effect of demographics, device type, and session interference on reliability.
Association among Cognitive Stress Appraisal, Chronic Stress, and Cognition in Cognitively Normal Older Adults: Preliminary Findings
Aduen, Paula, Badillo‐Cabrera, Alex L, Vila‐Castelar, Clara , Noriega‐Makarskyy, Daisy, Munera, Diana, Lucas, John A. , Kirschbaum, Clemens , Slavich, George M. , Quiroz, Yakeel T.

Mayo Clinic

Alzheimer's & Dementia | January 9, 2025 | Volume: 20 | Issue: S8 | Pages: No page available

10.1002/alz.095545 Get It

AbstractBackgroundCharacterizing stress can inform our understanding of direct and indirect pathways impacting mental and physical health outcomes, including age‐related cognitive decline. Chronic stress has been strongly associated with increased risk for cognitive decline, and hair cortisol concentration (HCC) has emerged as a viable neuroendocrine biomarker for its quantification. Cognitive appraisal of stress (CAS) provides key insight into the cognitive framework for responding to a given stressor. We implemented a multi‐pronged approach to evaluate chronic stress and examined its relation to cognition in older adults.MethodParticipants were 22 cognitively normal individuals (x̄ MMSE = 29.33, 0.92; x̄ age: 67.3 ± 8.8 years old, 17.0 ± 2.9 years of education, 54.5% female, 92.6% Non‐Hispanic White). Participants completed the Stress and Adversity Inventory (STRAIN) assessing lifetime stressor exposure and the Primary and Secondary Cognitive Appraisal Scale (PSCAS). HCC was used as a neuroendocrine biomarker of chronic stress. A brief cognitive battery assessing episodic memory and executive functions (Digit Span, HVLT‐R, Trail Making Test, Letter Fluency) and mood/anxiety measures were completed. To correct for skewness, log‐transformed HCC values were used for Pearson and partial correlation analyses controlling for age and education.ResultLifetime stressor exposure and CAS were not significantly related to cognitive performance (all ps > 0.05). There was a marginally significant association between HCC and executive functions (r = ‐0.41, p = 0.08). Total lifetime stressor count, chronicity, and severity were unrelated to symptoms of depression and anxiety (all ps > 0.05). Although lifetime stressor exposure and mood were not significantly related to HCC, higher HCC was associated with higher perceived control of stress (r = 0.45, p = 0.03).ConclusionHCC may be more sensitive to CAS rather than to objective stressor exposure. This highlights the potential of interventions targeted at improving coping in those with chronic stress. Results are preliminary, and the present study will explore impact of social and structural determinants of health on chronic stressor exposure, appraisal, and cognition.
Evidence‐based Clinical Practice Guideline on the Use of Blood‐based Biomarkers in Alzheimer’s Disease: Presentation of Preliminary Evidence, and Opportunity for Public Comment
Edelmayer, Rebecca M. , Allen, Laura A., Galasko, Douglas R., Okhravi, Hamid , Paczynski, Madeline , McAteer, Mary Beth , Kahaleh, Lara, Tampi, Malavika P. , Hansson, Oskar , Whitson, Heather E. , Galasko, Douglas R., Karikari, Thomas K. , Schindler, Suzanne E. , Suárez‐Calvet, Marc , Teunissen, Charlotte E. , Zetterberg, Henrik , Mahinrad, Simin , Pahlke, Sarah

Mayo Clinic

Alzheimer's & Dementia | January 9, 2025 | Volume: 20 | Issue: S8 | Pages: No page available

10.1002/alz.095319 Get It

AbstractBackgroundThe rapid development of blood‐based biomarkers (BBMs) has improved Alzheimer’s disease (AD) diagnostics with some tests now potentially suitable for clinical use. This aligns with the clinical availability of anti‐Aβ immunotherapies for early symptomatic AD, where BBMs can help address the increasing need for more rapid and early diagnosis. Clinical practice guidelines (CPG) can help guide healthcare professionals in incorporating BBMs into their clinical practice. The Alzheimer’s Association is collaborating with methodologists and a panel of 11 clinical and subject‐matter experts to develop a CPG for specialists, informed by a systematic review, on the use of BBMs for AD.MethodThe panel drafted several clinical questions prioritizing two questions on the use of BBMs in cognitively impaired or cognitively unimpaired individuals as the populations of immediate interest. Plasma p‐tau and Aβ biomarkers tests are index tests, and amyloid PET imaging, neuropathology, and CSF are reference standards. Experts in the GRADE (Grading of Recommendations, Assessment, Development, and Evaluations) approach are conducting a systematic review of the diagnostic accuracy of BBMs index tests by searching three databases (Pubmed, Embase, Cochrane Library) and will include assessments of the quality of collected evidence to inform the panel’s decision‐making process. Patients/caregivers and key external organizations will be engaged throughout.ResultThis session will cover preliminary evidence for answering the two clinical questions. At the time of abstract submission, the search strategy resulted in 880 titles/abstracts for the study selection process. Data abstraction, analysis, and evidence development are pending. Recommendations for answering clinical questions will be developed after July 2024, and all recommendations will be finalized and published by early 2025.ConclusionThe integration of BBMs into clinical care offers the potential to improve earlier and more accurate AD diagnosis for a broader patient population and expand access to new AD therapies. The development of evidence‐based CPGs is a critical step forward in optimizing and standardizing the clinical use of BBMs. As the field of AD diagnostics and treatment continues to evolve, this CPG on the use of BBMs for AD will expand and be regularly updated to include new target audiences/settings, patient populations, and associated evidence.
Evaluating DTI‐ALPS, an imaging surrogate for glymphatic clearance, in a large population‐based sample
Satpathi, Siddhartha , Przybelski, Scott A. , Raghavan, Sheelakumari, Gunter, Jeffrey L. , Petersen, Ronald C. , Radford, Jonathan Graff, Reid, Robert I. , Raghavan, Sheelakumari , Knopman, David S. , Cogswell, Petrice M. , Jack, Clifford R. , Vemuri, Prashanthi

Mayo Clinic

Alzheimer's & Dementia | January 9, 2025 | Volume: 20 | Issue: S2 | Pages: No page available

10.1002/alz.087185 Get It

Abstract Background Diffusion tensor imaging along perivascular spaces index (DTI‐ALPS), which measures diffusivity increases in the perivascular spaces along the medullary veins, is being increasingly utilized as a surrogate marker of glymphatic clearance (Taoka et. al. Jpn J Radio 2017). Lower DTI‐ALPS index means higher measured diffusivity from the perivascular space, and so it is expected to decrease with age. However, correlation with aging and dementia markers have not been systematically evaluated. The goal of this work was to automatically estimate DTI‐ALPS in a large sample and evaluate the variance explained by various demographic and imaging markers. Methods We identified 2739 participants aged 30+ years (mean 69.6, 48% female, 88% CU) in the population‐based Mayo Clinic Study of Aging with diffusion MRI. We estimated DTI‐ALPS through automated placement of regions as published previously (Liu et al. AAIC 2023) and shown in Figure 1. We examined the associations of DTI‐ALPS with demographics (age, sex), vascular risk (cardiovascular and metabolic condition score), clinical data (diagnosis, global cognition) and imaging markers (white matter hyperintensity (WMH), global amyloid load from PIB‐PET, and the temporal meta‐ROI Tau‐PET SUVR) using partial Pearson correlations and ANCOVA with adjustments for age and sex. Results DTI‐ALPS was negatively correlated with age, higher in females, declined with vascular risk, and lower in MCI/dementia groups (Figure 2). Higher WMH and higher amyloid were associated with lower DTI‐ALPS whereas Tau‐PET SUVR was not associated with DTI‐ALPS. Conclusions DTI‐ALPS can be automatically computed in large samples. Vascular risk and WMH had stronger associations with the computed DTI‐ALPS compared to AD biomarkers (amyloid and tau) suggesting that the surrogate was more likely linked to vascular injury.
Pemphigoid vegetans mit rezidivierenden, nicht heilenden Geschwüren bilateral an den retroaurikulären Sulci
Yang, Eilene, Maniam, Ganesh , Camilleri, Michael , Nguyen, Giang H.

Mayo Clinic

JDDG: Journal der Deutschen Dermatologischen Gesellschaft | January 9, 2025 | Volume: 23 | Issue: 1 | Pages: 112-113

10.1111/ddg.15595_g Get It

Blood‐based biomarkers of systemic inflammation, metabolic function, and vascular injury are elevated in patients with rapid progressive neurodegenerative disease
Satyadev, Nihal , Piura, Yoav , Graff‐Radford, Neill R. , Kuchenbecker, Lindsey A. , Tipton, Philip W. , Brier, Matthew R. , Dunham, Steven , O’Bryant, Sid E. , Day, Gregory S.

Mayo Clinic

Alzheimer's & Dementia | January 9, 2025 | Volume: 20 | Issue: S2 | Pages: No page available

10.1002/alz.090378 Get It

AbstractBackgroundPatients with rapid progressive Alzheimer disease and related dementias (rpAD/ADRD) develop dementia within 1 year or incapacitation within 2 years of symptom onset. We previously showed that selected CSF biomarkers of neuronal injury (NfL, VILIP‐1), AD neuropathology (p‐tau181), and neuroinflammation (GFAP, MCP‐1, sTREM2) measured at presentation associated with etiologic diagnoses and reliably differentiated patients with treatment‐responsive causes of rapid progressive dementia. However, no differences were identified between CSF biomarkers in patients with rapid and typical progressive forms of AD/ADRD, leaving key questions unanswered concerning the mechanisms that drive rpAD/ADRD. Blood‐based biomarkers may inform the systemic factors that contribute to rpAD/ADRD, including the systemic inflammation, metabolic function, and vascular injury.MethodsBiomarkers of systemic inflammation (Eotaxin‐3, IFN‐γ, IL‐1b, IL‐2, IL‐4, IL‐6, IL‐8, IL‐10, IL‐12p70, IL‐13, TARC, TNF‐α), metabolic function (A2M, B2M, FABP‐3, FVII, I‐309, IL‐18, PPY, TNC, TPO), and vascular injury (CRP, SAA, sICAM‐1, sVCAM‐1) were measured in plasma obtained at presentation from patients with rpAD/ADRD (n=29) and age‐ and sex‐ similar participants with typical progressive AD/ADRD (n=39) enrolled in prospective studies of memory and aging at Mayo Clinic in Florida. Biomarker measures were completed at the University of North Texas Institute for Translational Research using Meso Scale Discovery multiplexed assays. Biomarker concentrations were compared between groups using univariate analyses; potential predictors (p<0.05) were further evaluated via step‐wise multivariate logistic regression.ResultsMarkers of vascular injury (SAA, CRP, sICAM‐1), metabolic function (I‐309, TPO), and systemic inflammation (Eotaxin‐3, TARC, TNF‐α) were increased in patients with rapid versus typical progressive AD/ADRD (p<0.05). Eotaxin‐3, I‐309, and SAA were independently associated with rpAD/ADRD in multivariable model after controlling for age and sex. The overall model correctly characterized 86.8% of patients, with an area under the curve of 0.864 (95%CI: 0.777‐0.950; p<0.001).ConclusionBlood‐based biomarkers of systemic inflammation, metabolic function, and vascular injury were elevated at presentation in patients with rapid vs typical AD/ADRD. These findings may provide additional insights into the mechanisms that drive rpAD/ADRD. Longitudinal measures from larger cohorts are needed to decipher the relationship between candidate biomarkers and rpAD/ADRD.